ORTHOCELL LIMITED — Board/Management Information 2018

Mar 25, 2018

==> picture [594 x 111] intentionally omitted <==

Prof. Giuseppe Luongo Appointed to Orthocell Advisory Board

• Distinguished Professor and globally recognised expert in maxillofacial surgery, Dr. Giuseppe Luongo, appointed to Orthocell’s Medical and Scientific Advisory Board (MSAB)

• Experienced MSAB now in place to establish CelGro® as the best in class scaffold for bone and soft tissue repair

• Orthocell continues to execute its strategic market entry plans into Europe

Perth, Australia; 26 March 2018: Regenerative medicine company Orthocell Limited (ASX:OCC, “Orthocell” or the “Company”) is pleased to announce the appointment of Dr. Giuseppe Luongo to its Medical and Scientific Advisory Board (MSAB). This appointment, following the recent appointment of Dr. Massimo Simion, ensures Orthocell is well positioned to drive CelGro® into the European market and establish the scaffold as the highest quality, best in class medical device for oral bone and soft tissue regeneration procedures.

Orthocell Managing Director Paul Anderson said: “Dr. Luongo is a globally recognised thought leader in maxillofacial surgery and compliments the recent appointment of Dr. Simion to our MSAB. Attracting highly regarded surgeons to join our MSAB is reflective of the high-quality collagen medical devices manufactured by Orthocell. This represents another exciting milestone for the Company with the right experts in place to implement our strategic market entry plans for CelGro® in Europe.”

Dr. Luongo is a widely published and respected expert in maxillofacial surgery, specialising in maxillofacial reconstruction, advanced dental implant techniques and other dental guided bone regeneration procedures. Dr. Luongo has published numerous scientific articles in peer reviewed journals and is the editor of the oral health section of “Doctor Life” and co-editor of the Digital Section of BMC Oral Health journal. Dr Luongo is an adjunct Professor at the School of MaxilloFacial Surgery of the University Federico II of Naples. He is a Fellow of the International College of Dentistry, founding member of the Italian Academy of Osseointegration and Digital Dentistry Society and an active member of the Academy of Osseointegration.

Dr. Luongo said: “CelGro® is an innovative scaffold with key advantages over other products and supports high quality tissue repair. I am very excited to work collaboratively with the MSAB and Orthocell to establish CelGro® as the best in class scaffold for bone and soft tissue repair.”

The appointment of Dr. Luongo and Dr. Simion to Orthocell’s MSAB follows the recent regulatory approval in Europe (CE Mark) and represents a significant milestone in CelGro®’s pathway to market. The Company has agreed to issue Dr. Luongo and Dr. Simion each 250,000 unlisted options, exercisable at $0.34 expiring 3 years from the date of issue.

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au

==> picture [594 x 111] intentionally omitted <==

The Company is executing its strategic market entry plans into Europe, which incorporates the implementation of product distribution channels designed to optimise shareholder value. These potential product distribution channels include direct ordering mechanisms and external distributor arrangements in key European target markets.

For more information, please contact:

GeneraPaul AndOrthocelManaginP: +61 8E: paulan	l enquiriesersonl Limitedg Director9360 2888derson@orthocell.com.auInvestor enquiriesJoel SeahVesparum CapitalP: +61 3 8582 4800E: orthocell@vesparum.comMedia enquiriesHaley ChartresHales2 CommunicationsP: +61 423 139 163E: haley@h-squared.com.au

About Orthocell Limited

Orthocell is a regenerative medicine company focused on regenerating mobility for patients by developing products for the repair of a variety of soft tissue injuries. Orthocell’s portfolio of products include TGAlicensed cell therapies Autologous Tenocyte Implantation (Ortho-ATI®) and Autologous Chondrocyte Implantation (Ortho-ACI®), which aim to regenerate damaged tendon and cartilage tissue. The Company’s other major product is CelGro®, a collagen medical device which facilitates tissue repair and healing in a variety of orthopaedic, reconstructive and surgical applications. Orthocell recently received European regulatory approval (CE Mark) for CelGro®. The collagen medical device can now be marketed and sold within the European Union for a range of dental bone and soft tissue regeneration procedures and is being readied for first approval in the US.

For more information on Orthocell, please visit www.orthocell.com.au or follow us on Twitter @Orthocellltd and Linkedin www.linkedin.com/company/orthocell-ltd

Ph: +61 8 9360 2888 Fax: +61 8 9360 2899 www.orthocell.com.au